NCT01865305View on ClinicalTrials.gov

Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

59

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions

DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Interventions

DRUG

insulin degludec/insulin aspart 30

Single dose administrated subcutaneously (s.c., under the skin).

DRUG

insulin degludec/insulin aspart 40

Single dose administrated subcutaneously (s.c., under the skin).

DRUG

insulin degludec/insulin aspart 50

Single dose administrated subcutaneously (s.c., under the skin).

DRUG

insulin degludec

Single dose administrated subcutaneously (s.c., under the skin).

DRUG

insulin aspart

Single dose administrated subcutaneously (s.c., under the skin).

DRUG

biphasic insulin aspart 30

Single dose administrated subcutaneously (s.c., under the skin) as comparator.

DRUG

insulin degludec/insulin aspart 40

Single dose administrated subcutaneously (s.c., under the skin).

DRUG

insulin degludec/insulin aspart 50

Single dose administrated subcutaneously (s.c., under the skin).

DRUG

biphasic insulin aspart 30

Single dose administrated subcutaneously (s.c., under the skin).

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY